Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CervoMed Inc.CRVO · Entity 7338 | Chief Commercial and Business | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CervoMed Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-02-11 | Direct | 30,000 |
Reported balance
After 2026-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inozyme Pharma, Inc.
Report date July 01, 2025 · Filed July 03, 2025
Section 16 reporting ended · disclosed 2025-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Other · Disposed 21,743 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 41,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2035-03-10 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-01 · Disposition to issuer · Disposed 145,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
F3: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2026 Filed Feb 13, 2026 22:02 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001437749-26-004168 · rdgdoc.xml · derivative · entry 1 Winton Matthew · CIK 0001971400 · Chief Commercial and Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-02-11 F1 · derivative.exercise_date: The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 12:46 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 1,500 | $7.95 | $11,925.00 |
DisclosureSEC source: 0001437749-25-035655 · rdgdoc.xml · nonDerivative · entry 2 Winton Matthew · CIK 0001971400 · Chief Commercial and Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Shares purchased in open-market transactions. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 12:46 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 3,500 | $8.43 | $29,505.00 |
DisclosureSEC source: 0001437749-25-035655 · rdgdoc.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · Chief Commercial and Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Shares purchased in open-market transactions. Read SEC document |
| November 14, 2025 Filed Nov 17, 2025 14:01 UTC | CervoMed Inc. CRVO · Entity 7338 | PurchaseCommon Stock | 10,000 | $7.57 | $75,700.00 |
DisclosureSEC source: 0001437749-25-035308 · rdgdoc.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · Chief Commercial and Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Shares purchased in open-market transactions. F2 · price: The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.53 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range. Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 20:07 UTC | CervoMed Inc. CRVO · Entity 7338 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-030707 · rdgdoc.xml · derivative · entry 1 Winton Matthew · CIK 0001971400 · Chief Commercial and Business 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-10-06 F1 · derivative.exercise_date: Shares granted as an inducement award material to Dr. Winton's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Award vests in equal monthly installments over thirty-six (36) months on the last day of each month commencing October 31, 2025. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:08 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerStock Option (Right to Buy) · Derivative | 145,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0000950170-25-094098 · ownership.xml · derivative · entry 3 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 145,000 shares Expires 2035-03-10 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:08 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | Disposition to issuerRestricted Stock Units · Derivative | 41,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094098 · ownership.xml · derivative · entry 2 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,500 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 19:08 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | OtherCommon Stock | 21,743 | $4.00 | $86,972.00 |
DisclosureSEC source: 0000950170-25-094098 · ownership.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 16:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 14,355 | $0.74 | $10,622.70 |
DisclosureSEC source: 0000950170-25-090868 · ownership.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,743 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 16:29 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 2,490 | $0.77 | $1,917.30 |
DisclosureSEC source: 0000950170-25-049393 · ownership.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,388 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2024 through March 31, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on March 31, 2025, the last trading day of the purchase period. Read SEC document |
| March 11, 2025 Filed Mar 17, 2025 16:25 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantRestricted Stock Units · Derivative | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-040318 · ownership.xml · derivative · entry 2 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. F3 · derivative.exercise_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. F3 · derivative.expiration_date: The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028. Read SEC document |
| March 11, 2025 Filed Mar 17, 2025 16:25 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 145,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0000950170-25-040318 · ownership.xml · derivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2035-03-10 F1 · derivative.exercise_price: The exercise price represents the closing price of the Issuer's common stock on March 11, 2025. F2 · derivative.exercise_date: The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| September 30, 2024 Filed Oct 3, 2024 20:57 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 1,710 | $4.45 | $7,609.50 |
DisclosureSEC source: 0000950170-24-112694 · ownership.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,898 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2024 through September 30, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2024, the last trading day of the purchase period. Read SEC document |
| March 28, 2024 Filed Apr 3, 2024 17:23 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantCommon Stock | 3,188 | $3.33 | $10,616.04 |
DisclosureSEC source: 0000950170-24-041300 · ownership.xml · nonDerivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,188 F1 · kind: Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2023 through March 31, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 2, 2023, the first trading day of the purchase period. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 08:30 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0000950170-24-031878 · ownership.xml · derivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-03-12 F1 · derivative.exercise_date: The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 08:35 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001209191-23-022465 · doc4.xml · derivative · entry 1 Winton Matthew · CIK 0001971400 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-04-02 F1 · derivative.exercise_date: The option was granted on April 3, 2023 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.